Literature DB >> 12406910

Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX.

Afshin Ameri1, Sumiko Kurachi, Katsuo Sueishi, Mitsuhiro Kuwahara, Kotoku Kurachi.   

Abstract

Elevated circulatory levels of many blood coagulation factors are known to be a risk factor for deep vein thrombosis in humans. Here we report the first direct demonstration of a close association between elevated circulatory factor IX levels in mice with thrombosis as well as myocardial fibrosis. Transgenic mice overexpressing human factor IX at persistently high levels died at much younger ages than their cohorts expressing lower levels, or nontransgenic control animals. The median survival age of animals was inversely related to the circulatory levels of human factor IX. Prematurely dying animals had focal fibrotic lesions predominantly present in the left ventricular myocardium, and vasculatures in these lesions showed fibrin deposition. Thromboemboli were also present in other organs, including lung and brain. These observations support the hypothesis that persistently high circulatory levels of factor IX are a risk factor not only for thrombosis and/or thromboembolism, but also for myocardial fibrosis mimicking human myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406910     DOI: 10.1182/blood-2002-05-1581

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

2.  Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.

Authors:  Majed N Aljamali; Paris Margaritis; Alexander Schlachterman; Shing Jen Tai; Elise Roy; Ralph Bunte; Rodney M Camire; Katherine A High
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

3.  Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.

Authors:  Paul E Monahan; Junjiang Sun; Tong Gui; Genlin Hu; William B Hannah; David G Wichlan; Zhijian Wu; Joshua C Grieger; Chengwen Li; Thipparat Suwanmanee; Darrel W Stafford; Carmen J Booth; Jade J Samulski; Tal Kafri; Scott W J McPhee; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2015-01-21       Impact factor: 5.695

Review 4.  The Immune System in Tissue Environments Regaining Homeostasis after Injury: Is "Inflammation" Always Inflammation?

Authors:  Onkar P Kulkarni; Julia Lichtnekert; Hans-Joachim Anders; Shrikant R Mulay
Journal:  Mediators Inflamm       Date:  2016-08-11       Impact factor: 4.711

5.  Candidate SNP markers of reproductive potential are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.

Authors:  Irina V Chadaeva; Petr M Ponomarenko; Dmitry A Rasskazov; Ekaterina B Sharypova; Elena V Kashina; Dmitry A Zhechev; Irina A Drachkova; Olga V Arkova; Ludmila K Savinkova; Mikhail P Ponomarenko; Nikolay A Kolchanov; Ludmila V Osadchuk; Alexandr V Osadchuk
Journal:  BMC Genomics       Date:  2018-02-09       Impact factor: 3.969

6.  Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan.

Authors:  Darren J Baker; Meelad M Dawlaty; Tobias Wijshake; Karthik B Jeganathan; Liviu Malureanu; Janine H van Ree; Ruben Crespo-Diaz; Santiago Reyes; Lauren Seaburg; Virginia Shapiro; Atta Behfar; Andre Terzic; Bart van de Sluis; Jan M van Deursen
Journal:  Nat Cell Biol       Date:  2012-12-16       Impact factor: 28.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.